-
Annals of Internal Medicine Sep 1992
Topics: Adolescent; Adult; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Muscular Diseases; Peripheral Nervous System Diseases; Prospective Studies; Respiratory Insufficiency; Time Factors; Vecuronium Bromide
PubMed: 1354426
DOI: 10.7326/0003-4819-117-6-484 -
American Journal of Health-system... Jun 1999Factors driving the development of neuromuscular blocking agents are discussed. The goal of recent development of neuromuscular blocking agents is to develop agents with... (Review)
Review
Factors driving the development of neuromuscular blocking agents are discussed. The goal of recent development of neuromuscular blocking agents is to develop agents with fewer adverse effects than succinylcholine and greater control. Greater control can be achieved through a short duration of action and a fast onset, similar to that found with succinylcholine. Duration control can be achieved through rapid, reliable metabolism that is organ independent, as with cisatracurium, or that occurs in the liver, because this will fail only in patients with severe hepatic disease. Rapid onset can be achieved by giving higher doses of drugs that have a fast, reliable metabolism or a rapid distribution to tissue. This has been done with succinylcholine, cisatracurium, and mivacurium. It has been shown that a low-potency drug has a faster onset than a higher-potency drug, even at the same relative dose. Rocuronium was the first neuromuscular blocking agent marketed that was developed specifically as a low-potency drug for achieving a rapid onset. In a comparison with two other intermediate-duration neuromuscular blocking agents at equipotent doses, rocuronium's onset was about one minute, which was two minutes faster than that of either vecuronium or atracurium. Rapacuronium is an investigational intermediate-duration agent and is even less potent than rocuronium. Clinical studies have shown it to have a very rapid onset (about 50 seconds) and a short duration of action (15-25 minutes, depending on the dose). Its short duration of action will make it potentially useful for short surgical procedures and procedures in which nerve integrity must be monitored. At the same time, its onset time approaches that of succinylcholine. Recent advances have made the administration of neuromuscular blocking agents much easier because the newer nondepolarizing relaxants offer faster onset and greater control.
Topics: Animals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Neuromuscular Agents; Neuromuscular Blocking Agents; Time Factors; Vecuronium Bromide
PubMed: 10437712
DOI: 10.1093/ajhp/56.S14 -
Yonsei Medical Journal Mar 1992The interaction between succinylcholine (SCC) and non-depolarizers, atracurium or vecuronium was investigated in 36 cats of either sex using the sciatic nerve-anterior...
The interaction between succinylcholine (SCC) and non-depolarizers, atracurium or vecuronium was investigated in 36 cats of either sex using the sciatic nerve-anterior tibialis muscle preparation. Additionally, the relation of SCC to pseudocholinesterase activity was examined. The duration of action of vecuronium (6.5 +/- 1.3 to 7.3 +/- 2.2 minutes) in cats pretreated with SCC was greater than those (2.0 +/- 0.6 minutes) in non-pretreated cats. However, SCC had no influence on the duration of atracurium. The serum pseudocholinesterase activity was decreased after the injection of atracurium or neostigmine in contrast to vecuronium. The authors conclude that the prior administration of SCC prolongs the duration of vecuronium but not that of atracurium, and pseudocholinesterase activity is not related to the prolonging effect of SCC.
Topics: Animals; Atracurium; Cats; Female; Male; Succinylcholine; Vecuronium Bromide
PubMed: 1354401
DOI: 10.3349/ymj.1992.33.1.81 -
Anaesthesia Aug 1988
Topics: Anaphylaxis; Drug Hypersensitivity; Histamine Release; Humans; Leukocytes; Vecuronium Bromide
PubMed: 2458685
DOI: 10.1111/j.1365-2044.1988.tb04173.x -
Anesthesiology Jan 2001
Topics: Androstanols; Child; Child, Preschool; Humans; Infant; Injections, Intramuscular; Injections, Intravenous; Isoquinolines; Mivacurium; Neuromuscular Nondepolarizing Agents; Rocuronium; Time Factors; Vecuronium Bromide
PubMed: 11135714
DOI: 10.1097/00000542-200101000-00005 -
Anesthesiology Jan 1990
Comparative Study
Topics: Humans; Succinylcholine; Time Factors; Vecuronium Bromide
PubMed: 1967518
DOI: 10.1097/00000542-199001000-00040 -
Anaesthesia Feb 1988
Topics: Female; Humans; Kidney Diseases; Neostigmine; Vecuronium Bromide
PubMed: 2895593
DOI: No ID Found -
Anesthesiology Apr 1992
Topics: Blood Transfusion, Intrauterine; Female; Fetus; Gestational Age; Humans; Pregnancy; Rh Isoimmunization; Vecuronium Bromide
PubMed: 1347981
DOI: 10.1097/00000542-199204000-00025 -
Anaesthesia and Intensive Care Apr 2006
Topics: History, 20th Century; Humans; London; Netherlands; Neuromuscular Nondepolarizing Agents; Pancuronium; Vecuronium Bromide
PubMed: 16617633
DOI: 10.1177/0310057X0603400225 -
Veterinary Journal (London, England :... Jun 2012This study evaluated the use of sugammadex for reversal of profound neuromuscular blockade induced with rocuronium or vecuronium in dogs. Anaesthesia was induced and... (Randomized Controlled Trial)
Randomized Controlled Trial
This study evaluated the use of sugammadex for reversal of profound neuromuscular blockade induced with rocuronium or vecuronium in dogs. Anaesthesia was induced and maintained with isoflurane in oxygen in eight dogs on two occasions. Neuromuscular blockade was monitored using peroneal nerve stimulation and acceleromyography. Rocuronium 0.6 mg/kg or vecuronium 0.1mg/kg was administered intravenously (IV), followed 5 min later by sugammadex 8 mg/kg IV. Lag and onset time of rocuronium and vecuronium, lag time from sugammadex injection to recovery of first twitch response, recovery of T1/T0 to 25% and 75%, recovery index, and time to recovery of the train-of-four ratio (T4/T1) to 0.9 were recorded. Cardiovascular and respiratory parameters were also noted. Statistical analysis was performed using one-way ANOVA. Onset time for rocuronium (37 ± 18s; [mean ± SD]) was significantly shorter than for vecuronium (62 ± 15s) (P<0.04). No other significant differences were found between the two groups. After both rocuronium and vecuronium blockade, T4/T1 recovered to 0.9 in under 2 min after sugammadex (58.1 ± 67.8s and 98.1 ± 70.3s, respectively; P<0.32). Sugammadex can reverse profound neuromuscular blockade induced by vecuronium or rocuronium safely and rapidly in isoflurane-anaesthetised dogs.
Topics: Androstanols; Anesthesia, Inhalation; Anesthetics, Inhalation; Animals; Dogs; Dose-Response Relationship, Drug; Electric Stimulation; Female; Isoflurane; Male; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; Rocuronium; Sugammadex; Vecuronium Bromide; gamma-Cyclodextrins
PubMed: 22030475
DOI: 10.1016/j.tvjl.2011.08.034